BAS Research and Television Personality Montel Williams: First Medicinal Marijuana Manufacturing and Research License
BAS Research has announced California’s first medicinal marijuana manufacturing and research license, paving the way for production of medical-grade cannabis products. BAS focuses on creating high quality medicinal marijuana products. It believes will meet the unique needs of California patients who have recommendations from their physicians for any condition for which marijuana may provide relief.
Through the newly announced license, Berkley-based BAS has formed a partnership with television personality and high profile medical cannabis advocate Montel Williams to produce his new LenitivLabs brand of medicinal cannabis products in California.
Williams, who suffers from MS, has used medicinal cannabis to help manage his symptoms for 17 years. He is also a long-term advocate of legalizing medicinal cannabis, having worked to pass legislation in key states such as New Jersey, New York, Ohio, Pennsylvania, Maryland and Connecticut and others.
“As the country trends towards greater acceptance of recreational use, I started LenitivLabs because it’s critical that we continue to meet the unique needs of medicinal cannabis patients, so the partnership with BAS was a natural one for us and one which I’m excited about,” said Williams.
Two of BAS’s co-founders, Chief Operating Officer Doug Chloupek and Chief Executive Officer Dr Bao Le, have their own successful history with medicinal cannabis, which influenced the creation of the company.
Chloupek, who has been involved in the medicinal cannabis industry for 20 years, was one of California’s first recipients of medicinal cannabis in 1997. And Dr Le, whose son was diagnosed with autism and epilepsy, has used medicinal cannabis products to manage the seizures and night terrors associated with his son’s condition.
“I’ve experienced the benefits of medicinal cannabis first-hand and, unfortunately, seen the effects of people, especially those with the most serious illnesses, not having access to quality-controlled products to support their medical conditions,” said Chloupek.
“We will continue to push new boundaries with our research to create innovative products because we know the power medicinal cannabis has to support a wide range of medical conditions.”
Dr. Le’s passion for starting BAS is a personal endeavor. After learning that his youngest son is autistic, he committed his life to finding safe and holistic alternative treatment for children with similar conditions. “I am doing this for my son and to help others benefit from medicinal cannabis,” said Dr. Le.
The third of the company’s founders, Chief Strategy Officer Ernie Arreola, also has a long history within the medicinal cannabis industry as the co-founder and former CEO of San Jose Collective Lux Wellness Center and board member of non-profits Sensible San Jose and Citizens Coalition for Patient Care.
Over the next 12 months, BAS will partner with a renowned pain, neurological, and cancer physician as well as other medical professionals to hold new cannabis product investigations. It will also file with the appropriate organizations with the aim to launch clinical trials involving its medicinal cannabis products.
BAS also provides a range of services for licensed and compliant California-based collectives, including extraction and contract processing, private label manufacturing, packaging and labelling and IP formulation.
The new line of BAS medical products is on target to begin production in Q1 2017, pending the completion of the company’s neuropathic pain investigation studies.
BAS has been 100% operational and fully licensed with a permit for Cannabis Manufacturing and Processing as of June 2016.
DISCLAIMER: “The statements herein about products have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease.”
For more information, visit: http://www.basresearch.com and http://www.lenitivlabs.com/.